HIV as a chronic disease

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 9, Issue 2, 2009, Pages 125-128

  Mahungu, Tabitha W ^a   Rodger, Alison J ^a   Johnson, Margaret A ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Chronic disease; Highly active antiretroviral therapy; HIV

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; INTEGRASE INHIBITOR; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGING; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIVIRAL RESISTANCE; ARTICLE; BONE DENSITY; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; CHRONIC DISEASE; DELAYED DIAGNOSIS; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ERYTHEMA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; METABOLIC DISORDER; MORTALITY; MYOPATHY; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PLACENTAL TRANSFER; RESPIRATORY TRACT DISEASE; SEXUALLY TRANSMITTED DISEASE; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS DIAGNOSIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 69049085852     PISSN: 14702118     EISSN: 14734893     Source Type: Journal    
DOI: 10.7861/clinmedicine.9-2-125     Document Type: Article

References (36)

1. Centers for Disease Control and Prevention. Pneumocystis pneumonia - Los Angeles. Morb Mortal Wkly Rep 1981;30:250-2.
2. Joint United Nations Programme on HIV/AIDS. 2007 AIDS epidemic update: Latest developments in the global AIDS epidemic. Geneva: UNAIDS, 2007.
3. Health Protection Agency. HIV in the United Kingdom: 2008 report. London: HPA, 2007.
4. Markowitz M, Mohri H, Mehandru S et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: A case report. Lancet 2005;365:1031-8.
5. Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W. The characterization of non-progressors: Long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993;7:1159-66.
6. Lohse N, Hansen AB, Pedersen G et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87-95.
7. Geskus RB, Prins M, Hubert JB et al. The HIV RNA setpoint theory revisited. Retrovirology 2007;4:65.
8. Siliciano JD, Siliciano RF. A long-term latent reservoir for HIV-1: discovery and clinical implications. J Antimicrob Chemother 2004;54:6-9.
9. Lampe FC, Johnson MA, Lipman MC et al. Viral breakthrough after suppression with highly active antiretroviral therapy: Experience from 233 individuals with viral loads less than 50 copies/ml followed for up to four years. AIDS 2003;17:768-70.
10. Murphy R, da Silva BA, Hicks CB et al. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1 infected patients. HIV Clin Trials 2008;9:1-10.
11. Calmy A, Hirschel B, Cooper DA, Carr A. Clinical update: Adverse effects of antiretroviral therapy. Lancet 2007;370:12-4.
12. Mallal S, Phillips E, Carosi G et al. HLA-B*5071 screening for hypersensitivity to abacavir. N Engl J Med 2008;358:568-79
13. Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5071 screening and abacavir hypersensitivity: A single centre experience. AIDS 2007;21:2533-4.
14. Haubrich RH, Riddler S, DiRienzo G et al. Metabolic outcomes of ACTG 5142: A prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection. Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, 2007, abstract 35.
15. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003;36:1585-92.
16. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349: 1993-2003.
17. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
18. Gross R, Yip B, Wood E et al. Boosted PIs are more forgiving of suboptimal adherence than non-boosted PIs or NNRTIs. Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, 2006, abstract 533.
19. Booth CL, Geretti AM. Prevalence and determinants of transmitted drug resistance in HIV-1 infection. J Antimicrob Chemother 2007;59: 1047-56.
20. Gazzard B, BHIVA Treatment Guidelines Writing Group. British HIV Association (BHIVA) guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563-608
21. Mack KA, Ory MG. AIDS and older Americans at the end of the twentieth century. J Acquir Immune Defic Syndr 2003;33(Suppl2): S68-S75.
22. Douek DC, McFarland RD, Keiser PH et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998;396:690-5.
23. Perez JL, Moore RD. Greater effect of highly active antiretroviral therapy on survival in people aged > or = 50 years compared with younger people in an urban observational cohort. Clin Infect Dis 2003;36:212-8.
24. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004;18:51-8.
25. 3 compared with the general population. Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston. 2008, Abstract 141.
26. Clumeck N, Pozniak A, Raffi F, EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008;9:65-71.
27. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2008;1-128. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf
28. Sabin CA, Smith CJ, Gumley H et al. Late presenters in the era of highly active antiretroviral therapy: Uptake of and responses to antiretroviral therapy. AIDS 2004;18:2145-51.
29. Foster CJ, Lyall EG. HIV in pregnancy: Evolution of clinical practice in the UK. Int J STD AIDS 2006;17:660-7.
30. Bailey RC, Moses S, Parker CB et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: A randomised controlled trial. Lancet 2007;369:643-56.
31. Gray RH, Kigozi G, Serwadda D et al. Male circumcision for HIV prevention in young men in Rakai, Uganda: A randomised controlled trial. Lancet 2007;369:657-66.
32. Cardo DM, Culver DH, Ciesielski CA et al. A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure. Centres for Disease Control and Prevention Needlestick Suerveillance Group. N Engl J Med 1997;337:1458-90.
33. Fisher M, Benn P, Evans B et al, Clinical Effectiveness Group (British Association for Sexual Health and HIV). UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure. Int J STD AIDS 2006;17:81-92.
34. Subbarao S, Otten RA, Ramos A et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against simian human immunodeficiency virus infection in macaques given multiple virus challenges. J Infect Dis 2006;194:904-11.
35. British HIV Association. British HIV association guidelines on HIV and chronic hepatitis. London: BHIVA, 2004.
36. Gerretti AM, BHIVA Immunization Writing Committee, Brook G et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008;9:795-848.